Search - tctmd.com

Displaying 81 - 100 of 191

Sort: Relevancy | Date

Presentation TCT 2018

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Presenter: Anibal A. Damonte

September 21, 2018

Presentation The Structural Heart Disease Summit 2018

Post LAA Closure Anticoagulation/Antiplatelet Regimens: Data and Practice

Presenter: Josep Rodés-Cabau

June 22, 2018

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

VTE and PFO Closure: Device? Anticoagulation? Both?

Presenter: Mark Reisman, Brian K. Whisenant, Christian Spies

November 01, 2017

Presentation TCT 2017

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

Presenter: Robert A. Harrington, Kurt Huber, Christopher B. Granger

November 01, 2017

Presentation TCT 2017

Guidelines and Expert Consensus on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI: How Strong Is the Evidence?

Presenter: Robert A. Harrington, Kurt Huber, Jean-François Tanguay

November 01, 2017

Presentation TCT 2017

Topic 1: Anticoagulation After TAVR Should Now be Standard of Care CON!

Presenter: Adrian P. Banning, Ted Feldman, Bernard Prendergast

November 01, 2017

Presentation TCT 2017

Topic 1: Anticoagulation After TAVR Should Now be Standard of Care PRO!

Presenter: Adrian P. Banning, Ted Feldman, Raj Makkar

November 01, 2017

Presentation TCT 2017

TCT 92: Polyvascular Disease and Risk of Major Cardiovascular Events in Peripheral Artery Disease - Insights From EUCLID

Presenter: Kurt Huber, Jamil Abdalla Saad, Antonio Gutierrez, MD

October 31, 2017

Presentation TCT 2017

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Presenter: Kurt Huber, Jamil Abdalla Saad, Dimitrios Alexopoulos, Antonio L. Bartorelli, Bjorn Redfors, Carlos E. Uribe

October 31, 2017

Presentation TCT 2017

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

Presenter: Peter C. Block, Lars Sondergaard, Tarun Chakravarty, MD

October 31, 2017

Presentation TCT 2017

TCT 90: HAS-BLED Score and Other Predictors of Bleeding in Catheter-Directed Thrombolysis for Pulmonary Embolism

Presenter: Kurt Huber, Jamil Abdalla Saad, Kara Denby, MD

October 31, 2017

Presentation TCT 2017

TCT 50: Impact of Anticoagulation Therapy on Valve Hemodynamic Deterioration Following Transcatheter Aortic Valve Replacement

Presenter: Peter C. Block, Lars Sondergaard, Maria Del Trigo, MD

October 31, 2017

Presentation TCT 2017

TCT 89: Tradeoff Between Myocardial Infarction and Bleeding in Relation to Bleeding Risk - Insights From PARIS Registry

Presenter: Kurt Huber, Jamil Abdalla Saad, Sabato Sorrentino, MD

October 31, 2017

Presentation TCT 2017

Anticoagulation Following DVT/PE Intervention: What, When, Why, and for How Long?

Presenter: Michael R. Jaff, Robert A. Lookstein, Teresa L. Carman

October 30, 2017

Presentation SOLACI 2017

Prevention of Valvular Thrombosis: Antiaggregation or Anticoagulation?

Presenter: Fernando Pineda

August 02, 2017

Presentation LAA 2017

Real-World Outcomes in Anticoagulation Indicated and Contraindicated Patients

Presenter: Horst Sievert

July 21, 2017

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

Presentation ISET 2017

Anticoagulation Following DVT: Agents and Length of Treatment

Presenter: Ian del Conde

February 04, 2017

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Advertisement

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Post LAA Closure Anticoagulation/Antiplatelet Regimens: Data and Practice

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

VTE and PFO Closure: Device? Anticoagulation? Both?

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

Guidelines and Expert Consensus on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI: How Strong Is the Evidence?

Topic 1: Anticoagulation After TAVR Should Now be Standard of Care CON!

Topic 1: Anticoagulation After TAVR Should Now be Standard of Care PRO!

TCT 92: Polyvascular Disease and Risk of Major Cardiovascular Events in Peripheral Artery Disease - Insights From EUCLID

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

TCT 90: HAS-BLED Score and Other Predictors of Bleeding in Catheter-Directed Thrombolysis for Pulmonary Embolism

TCT 50: Impact of Anticoagulation Therapy on Valve Hemodynamic Deterioration Following Transcatheter Aortic Valve Replacement

TCT 89: Tradeoff Between Myocardial Infarction and Bleeding in Relation to Bleeding Risk - Insights From PARIS Registry

Anticoagulation Following DVT/PE Intervention: What, When, Why, and for How Long?

Prevention of Valvular Thrombosis: Antiaggregation or Anticoagulation?

Real-World Outcomes in Anticoagulation Indicated and Contraindicated Patients

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Anticoagulation Following DVT: Agents and Length of Treatment

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content